Trials / Completed
CompletedNCT04649580
United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting
A Cross-Sectional Patient-Reported Study To Assess The Patient Preference Of Treatment Administration Setting, Impact On Health-Related Quality Of Life, Work Productivity, Wider Societal Costs And Healthcare Utilisation For Patients With Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Prescribed Somatuline® Autogel® In A Homecare Setting and Hospital Setting.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare utilisation, societal cost, work productivity and health-related quality of life (HRQoL)
Conditions
Timeline
- Start date
- 2021-04-27
- Primary completion
- 2022-06-05
- Completion
- 2022-06-05
- First posted
- 2020-12-02
- Last updated
- 2024-12-17
Locations
5 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04649580. Inclusion in this directory is not an endorsement.